Popular Articles

Brain Changes Observed In Unimpaired Older Humans Could Be Early Warning Of Alzheimer's
New research has uncovered an early disruption in the process of memory formation in older humans who exhibit some early brain changes associated with Alzheimer"s disease (AD) but show little or no memory impairment. The work, published by Cell Press in the July 30th issue of the journal Neuron, sheds light on the role of amyloid protein in memory impairment and may lead to development of strategies for predicting and treating cognitive decline in individuals who are at-risk for AD.

Turkish Ministry Of Health Purchases Two CyberKnife(R) Systems - Expands Patient Access To The Benefits Of Whole Body Radiosurgery
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
News of the day
Protalix Holds Pre-NDA Meeting With FDA For PrGCD For The Treatment Of Gaucher Disease
Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced that the Company held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting was to discuss the a proposed new drug application (NDA) submission for prGCD, a new proprietary plant-cell expressed recombinant form of glucocerebrosidase, for the treatment of Gaucher disease and to confirm the clinical, nonclinical and chemistry requirements for the proposed NDA filing.
Cardiovascular

Repeated Stress Signals Made In Cells With Metabolism-Associated Disease Encourage The Growth Of Invading Bacteria

Mitochondrial diseases disrupt the power generating machinery within cells and increase a person"s susceptibility to bacterial infection, particularly in the lungs or respiratory tract. A new study published in Disease Models & Mechanisms (DMM), shows that infection with the pneumonia causing bacteria Legionella, is facilitated by an increased amount of a signaling protein that is associated with mitochondrial disease. Patients with mitochondrial disease exhibit a wide range of symptoms including diabetes, blindness, deafness, stroke-like episodes, epilepsy, ataxia, muscle weakness and kidney disease. The metabolic abnormalities that cause these effects also induce a stress signal intended to help the body overcome its energy deficit. The stress-signal induces the production of more mitochondria, the energy generating "powerplants" of the body, in the hopes that more mitochondria will result in a better power supply. Researchers now show that the stress-signal associated with mitochondrial disease facilitates the growth and reproduction of the lung-infecting bacteria, Legionella. Cells with mitochondrial disease increase their production of a signaling protein called AMP-activated protein kinase (AMPK), to promote the generation of more energy producing mitochondria. Infectious bacteria, like Legionella, target the mitochondria and might use them to supplement their own needs and survival requirements. By manipulating AMPK levels, scientists were able to directly influence the ability of bacteria to replicate inside of the single-celled organism, Dictyostelium. Striking similarities that exist between simple organisms like Dictyostelium and humans allow scientists to use them to understand human disease. Dictyostelium is a free-living amoeba whose rapid movements make it useful to study motility and energy regulation, and in this case, the association between energy regulation and susceptibility to infection. Like humans, Dictyostelium can be infected by Legionella and quickly responds by producing a host of metabolism-associated proteins. Another similarity between humans and Dictyostelium is that both use AMPK as an internal sensor to coordinate energy synthesis with energy needs. However, unlike humans, researchers can infect Dictyostelium with germs like Legionella in a controlled environment and determine the influence of various parameters on the course of infection. The report titled "Legionella pneumophila multiplication is enhanced by chronic AMPK signalling in mitochondrially diseased cells" was written by Lisa Francione, Paige K. Smith, Sandra L. Accari, Paul B. Bokko and Paul Fisher at La Trobe Univeristy in Australia, Salvatore Bozzaro at University of Turin in Italy and Phillip E Taylor and Peter L. Beech at Deakin University in Australia. The study is published in the September/October 2009 issue of the new research journal, Disease Models & Mechanisms (DMM), published by The Company of Biologists, a non-profit based in Cambridge, UK. Kristy Kain The Company of Biologists


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):